Are GLP-1 Approved for Weight Loss? Exploring the Latest in Weight Management

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes — several GLP-1 receptor agonists are FDA-approved for chronic weight management, but not all of them are, and the ones most people name usually are not the ones that hold the approval. Wegovy (semaglutide) and Zepbound (tirzepatide) carry weight-management indications. Ozempic and Mounjaro do not — they are type 2 diabetes products containing the same two molecules. Saxenda (liraglutide 3 mg) has held a weight-management approval since 2014, and Foundayo (orforglipron), approved April 1, 2026, added the first oral small-molecule entrant.

The Approved Weight-Management Set

Wegovy injection is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition. It also carries a cardiovascular risk reduction indication and, under accelerated approval, an indication for noncirrhotic MASH with moderate to advanced fibrosis.

Wegovy tablets, approved December 22, 2025, sit inside the same prescribing information but carry a narrower set of indications — the cardiovascular and weight reduction ones, without the pediatric or MASH uses.

Zepbound is indicated for chronic weight management in adults with obesity or overweight plus a weight-related condition, and separately for moderate to severe obstructive sleep apnea in adults with obesity. Foundayo, an oral tablet, is indicated for chronic weight management with a labeled limitation of use against concomitant use with another GLP-1 receptor agonist.

The Products That Are Not Approved for Weight Loss

Ozempic is a GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. None of those is a weight indication.

Mounjaro is indicated only as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. Rybelsus and Ozempic tablets, covered by a single shared label, are likewise type 2 diabetes products with a cardiovascular risk reduction indication and no weight-management claim.

This is not a technicality. Coverage, prior authorization criteria and diagnosis coding all key off the approved indication, which is why a plan can cover one product and refuse another containing the identical molecule.

What the Approval Evidence Actually Showed

For semaglutide, STEP 1 ran 68 weeks in 1,961 adults and reported a mean body weight change of −14.9% versus −2.4% with placebo. Study 8 in the current Wegovy label ran 72 weeks in 1,407 participants and reported −18.8% at 7.2 mg and −15.5% at 2.4 mg versus −3.9% with placebo.

For tirzepatide, SURMOUNT-1 ran 72 weeks in 2,539 adults with obesity or overweight, excluding diabetes, and reported mean weight changes of −15.0%, −19.5% and −20.9% across three dosages versus −3.1% with placebo.

All of those trials layered the medication onto a reduced-calorie diet and increased physical activity, which is why the indications themselves are written as adjuncts to that combination.

Beyond Weight: What Else These Approvals Cover

The SELECT trial established that semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without diabetes, which is the basis for Wegovy’s cardiovascular indication.

Zepbound’s obstructive sleep apnea approval, granted in December 2024 on the basis of two 52-week randomised placebo-controlled studies in 469 adults, was the first medication approval for that condition. Wegovy’s MASH indication was granted under accelerated approval, which means continued approval may depend on confirmatory trial results.

The direction of travel is clear: these are being approved as cardiometabolic drugs, not purely as weight drugs, and the labels increasingly reflect outcomes beyond the scale.

Where Compounded Preparations Sit

Compounded semaglutide and tirzepatide are not on the approved list, because they are not FDA-approved finished products at all. The FDA states plainly that compounded drugs are not FDA approved and that it does not review them for safety, effectiveness or quality before marketing.

They are also not generics. The agency distinguishes compounded preparations from generic drugs, which must establish therapeutic equivalence to a reference product. No approved generic semaglutide or tirzepatide exists.

A compounded preparation is prepared by a state-licensed pharmacy pursuant to a prescription for an individual patient. That is a legitimate category with a real regulatory framework — it is simply a different category from an FDA-approved brand, and describing it otherwise misstates both the evidence and the law.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Which GLP-1 medications are FDA-approved for weight loss?

Wegovy (semaglutide injection and tablets), Zepbound (tirzepatide), Saxenda (liraglutide 3 mg) and Foundayo (orforglipron, approved April 1, 2026) hold chronic weight management indications. Ozempic, Mounjaro and Rybelsus do not — they are type 2 diabetes products, some with additional cardiovascular or kidney indications, but none with a weight-management claim.

Why is Ozempic not approved for weight loss if people lose weight on it?

Approval is granted for an application supported by specific trials, not for a molecule. Novo Nordisk submitted separate applications for the diabetes and obesity uses of semaglutide, with separate trial programmes and separate labeling. Weight change was measured in the diabetes trials, but glycemic endpoints were primary. Wegovy is the semaglutide product whose approval rests on obesity trials.

How much weight did people lose in the approval trials?

STEP 1 ran 68 weeks in 1,961 adults and reported a mean change of −14.9% with semaglutide 2.4 mg versus −2.4% with placebo. SURMOUNT-1 ran 72 weeks in 2,539 adults and reported −15.0%, −19.5% and −20.9% across three tirzepatide dosages versus −3.1% with placebo. All participants also received diet and physical activity counselling.

Is there an approved oral option?

Yes. Wegovy tablets were approved December 22, 2025 for cardiovascular risk reduction and weight reduction, and Foundayo (orforglipron) was approved April 1, 2026 as an oral tablet for chronic weight management. There is no FDA-approved oral tirzepatide. Rybelsus and Ozempic tablets are oral semaglutide products indicated for type 2 diabetes, not weight management.

Are compounded GLP-1 preparations approved for weight loss?

No. Compounded preparations are not FDA-approved finished products, and the agency does not review them for safety, effectiveness or quality before they are marketed. They are also not generic versions of any brand, because generics must establish therapeutic equivalence and no approved generic semaglutide or tirzepatide exists. They are prepared by state-licensed pharmacies against individual prescriptions.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.